Cargando…
Melittin-MIL-2 fusion protein as a candidate for cancer immunotherapy
BACKGROUND: Cytokine fusion protein that modulates the immune response holds great potential for cancer immunotherapy. IL-2 is an effective treatment against advanced cancers. However, the therapeutic efficacy of IL-2 is limited by severe systemic toxicity. Several mutants recombinant IL-2 can incre...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4888606/ https://www.ncbi.nlm.nih.gov/pubmed/27246873 http://dx.doi.org/10.1186/s12967-016-0910-0 |